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A B S T R A C T
Background: Occurrence of malignant ventricular tachyarrhythmias such as ventricular tachycardia and
ﬁbrillation (VT/VF) in hypertrophic cardiomyopathy (HCM) can be related to the extent of myocardial
ﬁbrosis. Although late gadolinium enhancement (LGE) on cardiovascular magnetic resonance (CMR)
imaging has been used to detect myocardial ﬁbrosis, few data exist regarding relationships between
CMR-determined myocardial ﬁbrosis and VT/VF in genotyped HCM populations.
Objective: We retrospectively investigated whether the extent of LGE can be increased in HCM patients
with VT/VF compared to those without VT/VF in the genotyped HCM population.
Methods and results: We studied 35 HCM patients harboring sarcomere gene mutations (TNNI3 = 22,
MYBPC3 = 12, MYH7 = 1) who underwent both CMR imaging and 24-h ambulatory electrocardiographic
monitoring. VT/VF were identiﬁed in 6 patients (2 men, mean age 55.0 years). The extent of LGE was
signiﬁcantly increased in patients with VT/VF (n = 6) compared with those without VT/VF (n = 29)
(18.6  14.4% vs. 8.3  11.4%, p = 0.04), although the LGE extent was not an independent predictor for the
occurrence of VT/VF. Applying a cut-off point 3.25%, episodes of VT/VF were identiﬁed with a sensitivity of
100%, speciﬁcity of 51.7%, positive predictive value of 30%, negative predictive value of 100%, and the area
under the curve of 0.767 (95% conﬁdence interval: 0.590–0.944).
Conclusion: These results demonstrate that myocardial ﬁbrosis determined by CMR imaging may be
increased in genotyped HCM patients with episodes of VT/VF. A further prospective study will be needed
to clarify the association between the LGE extent and arrhythmic events in HCM patients harboring
sarcomere gene mutations.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Hypertrophic cardiomyopathy (HCM) is an inherited cardiac
disease, and mutations in 11 or more genes encoding proteins of
the cardiac sarcomere (>1400 variants) are associated with HCM
[1,2]. Although the overall prognosis of HCM may not be
unfavorable, hereditary HCM with sarcomere gene mutations* Corresponding author at: Division of Cardiovascular Medicine, Kanazawa
University Graduate School of Medicine, 13-1 Takara-machi, Kanazawa 920-8641,
Japan. Tel.: +81 76 265 2259; fax: +81 07 234 4210.
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsmay be associated with increased cardiovascular events
[3,4]. Moreover, in some cases sudden death associated with
malignant ventricular tachyarrhythmias such as ventricular
tachycardia and ﬁbrillation (VT/VF) may occur, particularly in
young adults [5–7]. Under these conditions, the occurrence of
these arrhythmias may be related to the extent of myocardial
ﬁbrosis [8]. However, few clinical data exist regarding the
relationship between myocardial ﬁbrosis and occurrence of
ventricular tachyarrhythmia particularly in HCM with sarcomere
gene mutations.
Evaluation of late gadolinium enhancement (LGE) on cardio-
vascular magnetic resonance (CMR) imaging enables us to detect
myocardial ﬁbrosis and to examine whether LGE is associated with reserved.
T. Fujita et al. / Journal of Cardiology 66 (2015) 63–6864the occurrence of VT/VF in HCM [9,10]. In the present study, using
CMR imaging we investigated the correlation between the extent
of myocardial ﬁbrosis and VT/VF in HCM patients in whom
sarcomere gene mutations were identiﬁed.
Methods
Study patients
The diagnosis of HCM was based on the guidelines of the
American College of Cardiology Foundation/European Society of
Cardiology [11]. Patients with coronary artery disease, intrinsic
valve dysfunction, and idiopathic pulmonary artery hypertension
were excluded from the study. We screened for mutations in
sarcomere genes in 488 unrelated HCM probands (377 men) who
were diagnosed at Kanazawa University Hospital and afﬁliated
hospitals [12]. Sarcomere gene mutations were identiﬁed in 69 of
the 488 probands. Family studies of these 69 probands revealed an
additional 88 mutation carriers; thus in total 157 mutation carriers
were identiﬁed. Of these, 35 HCM patients harboring sarcomere
genes’ mutations who underwent both CMR and 24-h Holter
electrocardiogram (ECG) monitoring were included in this study.
All clinical evaluations for the 35 patients were performed from
2005 to 2009 at the Kanazawa University Hospital, and data were
retrospectively collected. Informed consent for genetic analysis
and use of clinical data for research was obtained from all subjects
or their guardians. The study was approved by the Bioethical
Committee on Medical Research, School of Medicine, Kanazawa
University.
Genetic analysis
Mutations in translated exons of the 8 common sarcomere
genes were screened: cardiac myosin binding protein C
(MYBPC3), cardiac myosin heavy chain (MYH7), cardiac regula-
tory and essential myosin light chains (MYL2 and MYL3), cardiac
troponin I (TNNI3), cardiac troponin T (TNNT2), cardiac tropo-
myosin (TPM1), and cardiac actin (ACTC1). Mutations were
screened using the polymerase chain reaction (PCR) and the
single-strand conformational polymorphism (SSCP) technique or
high resolution melting (HRM) analysis (LightScanner System,
Idaho Technology, Salt Lake City, UT, USA). For the abnormal SSCP
or HRM patterns, PCR products were directly sequenced to
identify mutations [4].Fig. 1. Methods for evaluation of the extent of late gadolinium enhancement (LGE). (A
measured by manual planimetry and were expressed as a percentage of total myocardClinical evaluations
The 35 HCM patients underwent 12-lead standard ECG, 24-h
ambulatory ECG monitoring, echocardiography, and CMR. All clinical
evaluations were performed from 2005 to 2009 at the Kanazawa
University Hospital, and data were retrospectively collected.
Standard M-mode and 2-dimensional echocardiographic studies
were performed by sonographers with knowledge of HCM diagnosis
but without knowledge of CMR parameters to avoid potential
measurement bias. Measured parameters included thicknesses of
the interventricular septum and left ventricular (LV) posterior wall
at the level of the tips of the mitral valve leaﬂets. Fractional
shortening was calculated as (end-diastolic dimension–end-systolic
dimension)/end-diastolic dimension. LV ejection fraction was
calculated with Simpson’s method [13]. Impaired systolic LV
function was deﬁned when LV ejection fraction was <50% [14].
CMR images were acquired by using a 1.5-T Signa MR unit (Echo
speed CVi) with a cardiac coil (GE Medical Systems, Milwaukee, WI,
USA). Fast spoiled gradient recalled acquisition cines were
acquired during 8-second breath-holds (the echo time/repetition
time 1.3/5.0 ms, ﬂip angle 308) in long-axis planes and sequential
8-mm short-axis slices (2 mm gap between slices) from the apex to
the atrioventricular ring. Intravenous gadolinium with diethyle-
netriamine pentaacetic acid was given (0.2 mmol/kg) and contrast-
enhanced images were acquired after 10–15 min in 8–10 identical
short-axis planes and 4-chamber view planes by using an
inversion-recovery segmented gradient echo. Inversion times
were adjusted to null normal myocardium (230–350 ms) with
voxel sizes of 2.0 mm  1.6 mm  8.0 mm [15]. Hyperenhanced
areas were calculated by manual planimetry in all short-axis slices
and the total areas of hyperenhancement are expressed as a
percentage of total myocardium (Fig. 1) [16,17]. All imaging
studies were analyzed separately by two observers without
knowledge of clinical ﬁndings. In patients with VT/VF, the areas
of LGE were indicated in the American Heart Association/American
College of Cardiology 17-segment model nomenclature [18].
Evaluation of arrhythmic events
Arrhythmic events were deﬁned as sudden cardiac death, non-
sustained VT, sustained VT, and VF. Documentation of these events
was based on records of VT/VF on an automated external
deﬁbrillator, 24-h Holter ECG, continuous ECG monitoring, the
use of an implantable deﬁbrillator, or the occurrence of sudden) Areas of LGE were measured in short-axis slices. (B) The total areas of LGE were
ium.
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three consecutive ventricular beats with a rate of more than
120 beats/min. These arrhythmic events which occurred after the
CMR examination were retrospectively collected using the electric
medical record system. Thus, the observation period began on the
date of the CMR examination and ended on the date of clinical data
collection.
Statistical analysis
Data are presented as the mean  standard deviation for
continuous variables. Continuous variables between the two groups
were compared using the Mann–Whitney U-test. Categorical
frequencies were compared using Fisher’s exact test. Receiver
operating characteristic (ROC) curves were plotted and the area
under the curve (AUC) was estimated to establish a cut-off of the
extent of LGE with appropriate sensitivity and speciﬁcity to detect
VT/VF. The optimum cut-off point was determined as the value
corresponding to the greatest accuracy (i.e. highest summed value for
sensitivity plus speciﬁcity values, with sensitivity and speciﬁcity
weighted equally). Variables associated with VT/VF were analyzed
with univariate and multivariate logistic regression analysis to
examine the association between patients with and without VT/VF
and to calculate odds ratio and 95% conﬁdence intervals after
controlling simultaneously for potential confounders. A linear
regression analysis was used to analyze the relationship between
the extent of LGE and plasma brain natriuretic peptide (BNP). A
p value <0.05 was considered statistically signiﬁcant. Data were
analyzed using SPSS Statistics 19.0 (SPSS Inc., Chicago, IL, USA).
Results
Patients’ proﬁles
Of the 35 HCM patients (12 men, mean age 54.9 years), 22 had a
TNNII3 mutation, 12 had a MYBPC3 mutation, and one had a MYH7Table 1
Clinical characteristics of the HCM patients according to the presence or absence of VT
Variable All patients (n = 35) 
Clinical characteristics
Age (years) 54.9  16.1 
Male, n (%) 12 (34.3) 
Systolic blood pressure (mmHg) 116.7  19.1 
Diastolic blood pressure (mmHg) 71.2  11.7 
Mean blood pressure (mmHg) 86.3  14.2 
BNP (pg/ml) 224.9  245.8 
Echocardiographic and CMR data
LAD (mm) 43.1  7.2 
IVST (mm) 15.2  3.8 
PWT (mm) 10.4  2.4 
MWT (mm) 16.3  4.7 
LVDd (mm) 46.1  7.2 
LVDs (mm) 30.3  8.2 
LVEF (%) 63.2  14.3 
LGE on CMR, n (%) 30 (85.7) 
the extent of LGE on CMR (%) 10.1  12.4 
Disease-causing gene
TNNI3, n (%) 22 (62.8) 
MYBPC3, n (%) 12 (34.3) 
MYH7, n (%) 1 (2.9) 
Medication
b-blockers, n (%) 22 (62.8) 
RAAS inhibitors, n (%) 17 (48.6) 
Amiodarone, n (%) 8 (22.9) 
HCM, hypertrophic cardiomyopathy; VT/VF, ventricular tachycardia/ventricular ﬁbri
resonance; IVST, interventricular septum thickness; LAD, left atrial dimension; LGE, lat
left ventricular end-systolic dimension; LVEF, left ventricular ejection fraction; MW
thickness; RAAS, renin-angiotensin-aldosterone system.mutation (Table 1). Plasma BNP levels were 224.9  245.8 pg/mL.
As for medication, 22 patients were treated with b-blockers, 17 with
angiotensin-converting enzyme inhibitors/angiotensin II receptor
inhibitors, and 8 with amiodarone. No patients were implanted with
implantable cardioverter-deﬁbrillators or cardiac resynchronization
therapy with deﬁbrillator on the date of the CMR examination, which
was the start date of the observation period. Interventricular septal
wall thickness was 15.2  3.8 mm, LV posterior wall thickness
10.4  2.4 mm, and maximal LV wall thickness 16.3  4.7 mm. LV
end diastolic dimension was 46.1  7.2 mm and systolic dimension
30.3  8.2 mm. LV ejection fraction was 63.2  14.3%. There were six
patients with impaired systolic LV function (LV ejection fraction
<50%). Left atrial dimension was 43.1  7.2 mm. LGE was found in
30 of the 35 patients (85.7%). The mean extent of LGE was
10.1  12.4%.
Occurrence of VT/VF and imaging parameters
With either conventional or continuous ECG recording, VT/VF
was retrospectively identiﬁed in 6 (17%) of the 35 HCM patients. Of
these six patients, VF was identiﬁed in four patients, and non-
sustained VT was recorded on 24-h Holter ECG or continuous ECG
monitoring in two patients. Sudden cardiac death was not
identiﬁed, although one death from aggravated heart failure was
identiﬁed. The mean observation periods of the total 35 patients,
29 patients without VT/VF, and 6 patients with VT/VF were
92.7  13.1 months, 93.6  13.0 months, and 88.5  14.1 months,
respectively. The six patients with VT/VF developed arrhythmic
events 28  25.6 months after the starting date of the observation
period. In the six patients with VT/VF, LGE was observed more
frequently in the inferolateral area than in the anteroseptal area
(p = 0.003) (Supplement Fig. S1).
Supplementary Fig. S1 related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.jjcc.2014.10.002.
The clinical characteristics of patients with or without VT/VF
are shown in Table 1. Plasma BNP levels, the LV end-diastolic and/VF.
VT/VF (+) (n = 6) VT/VF () (n = 29) p value
55.0  20.4 54.9  15.5 0.915
2 (33.3) 10 (34.5) 1.000
108.0  5.3 118.1  20.2 0.464
64.7  9.2 72.2  11.9 0.308
79.1  7.9 87.5  14.7 0.265
458.7  436.1 174.8  154.5 0.037
46.7  12.0 42.3  5.9 0.312
14.8  3.2 15.3  3.9 0.717
11.3  2.9 10.2  2.3 0.356
15.3  4.1 16.5  4.9 0.593
52.5  8.2 44.8  6.3 0.035
38.2  10.5 28.7  6.8 0.031
53.5  15.5 65.2  13.5 0.076
6 (100.0) 24 (82.8) 0.561
18.6  14.4 8.3  11.4 0.040
4 (66.7) 18 (62.1) 0.893
2 (33.3) 10 (34.5)
0 1 (3.4)
3 (50.0) 19 (65.5) 0.649
4 (66.7) 13 (44.8) 0.402
3 (50.0) 5 (17.2) 0.117
llation; BNP, plasma B-type natriuretic peptide; CMR, cardiovascular magnetic
e gadrinium enhancement; LVDd, left ventricular end-diastolic dimension; LVDs,
T, maximal left ventricular wall thickness; PWT, posterior left ventricular wall
Fig. 2. Representative magnetic resonance imaging in patients with hypertrophic cardiomyopathy (HCM) with (A) or without (B) ventricular tachyarrhythmias. (A) The image
was obtained from a 52-year-old female with the late gadolinium enhancement (LGE) (arrows) extent of 37.6%. The thickness of interventricular septum was 14 mm. (B) The
image was obtained from a 35-year-old female with the LGE (arrows) extent of 6.5%. The thickness of interventricular septum was 15 mm.
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patients with VT/VF compared to those without VT. Representative
CMR images of a patient with VT/VF or a patient without VT/VF are
shown in Fig. 2A and B, respectively. Further, the extent of LGE was
signiﬁcantly increased in patients with VT/VF compared with those
without VT/VF (18.6  14.4% vs. 8.3  11.4%, p = 0.04) (Fig. 3). There
was no difference in frequency of the disease-causing gene or in
echocardiographic LV thickness and ejection fraction between two
groups.
We next tested whether the LGE extent predicts the occurrence
of VT/VF in the 35 HCM patients; logistic regression analysesFig. 3. Comparison of the extent of late gadolinium enhancement (LGE) on
cardiovascular magnetic resonance (CMR) in hypertrophic cardiomyopathy
patients with vs. without ventricular tachycardia and ﬁbrillation (VT/VF). There
was a signiﬁcant difference in the extent of LGE between patients with and without
VT/VF (18.6  14.4% and 8.3  11.4%, respectively, p = 0.04).revealed that the LGE extent was not an independent predictor for
the occurrence of VT/VF. Nonetheless, it may be intriguing to
examine the diagnostic values of the LGE extent for predicting the
occurrence of VT/VF in the study population. ROC curve analysis
demonstrated that applying a cut-off point 3.25%, episodes of
VT/VF were identiﬁed with a sensitivity of 100%, speciﬁcity
of 51.7%, positive predictive value of 30%, negative predictive value
of 100%, and the area under the curve of 0.767 (95% conﬁdence
interval: 0.590–0.944) (Fig. 4).Fig. 4. Receiver operating characteristic (ROC) curve for the extent of late
gadolinium enhancement (LGE) and the occurrence of ventricular tachycardia and
ﬁbrillation (VT/VF). ROC curve analysis demonstrated that applying a cut-off point
3.25%, episodes of VT/VF were identiﬁed with a sensitivity of 100%, speciﬁcity of
51.7%, positive predictive value of 30%, negative predictive value of 100%, and the
area under the curve (AUC) of 0.767 [95% conﬁdence interval (CI): 0.590–0.944].
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The clinical manifestations of HCM can be remarkably variable,
ranging from near-normal life expectancy with no symptoms to
sudden cardiac death in youth [5–7]. Histopathologic abnormali-
ties of HCM include myocyte hypertrophy, disarray, and increased
interstitial and/or focal ﬁbrosis [19,20]. Myocardial ﬁbrosis
contributes to diastolic and/or systolic dysfunction, and the
occurrence of arrhythmic events in HCM [21–29]. Although little
has been known whether CMR-determined myocardial ﬁbrosis is
associated with arrhythmic events in genotyped HCM, we
demonstrated that the extent of LGE was increased in HCM
patients with VT/VF in whom sarcomere gene mutations were
identiﬁed (Table 1, Fig. 3).
Early studies regarding genotype–phenotype correlations of
HCM showed some signiﬁcant differences between phenotypes
observed at various disease-causing genes [2,30,31]. However,
taken as a whole, the value of genetic testing in HCM is often
criticized as being unable to predict the clinical course of mutation
carriers [2,12,32]. Indeed, no difference in frequency of disease-
causing genes was observed between HCM patients with VT/VF
and those without VT/VF (Table 1), indicating limitations of genetic
testing as a tool for risk stratiﬁcation in HCM. Together with
evidence in associations between LGE and cardiac events in HCM
[8–10,16,33,34], our ﬁndings indicate that it may be practical to
determine the extent of myocardial ﬁbrosis by LGE techniques in
HCM harboring sarcomere gene mutations.
Regarding prediction of fatal arrhythmias, LGE was not an
independent factor associated with occurrence of VT/VF in our
genotyped Japanese HCM population, while Hen et al. recently
reported that LGE may predict the occurrence of fatal arrhythmias
in a non-genotyped Japanese HCM population [35]. We have
previously reported that the presence of sarcomere gene mutation
may be associated with the increased occurrence of cardiac events
in HCM [4], suggesting that different genetic backgrounds of the
study populations could affect prognostic values of LGE in HCM.
The increased LGE extent in HCM patients with VT/VF raises
important issues regarding mechanisms of arrhythmogenicity in
HCM. Despite the correlations between CMR-determined ﬁbrosis
and arrhythmic events in HCM patients [8–10,16,22–29,33,34],
Wolf et al. have demonstrated that the extent of ﬁbrosis was not
correlated with ex vivo signal conduction properties or in vivo
electrophysiologically stimulated ventricular arrhythmias in
genetically engineered HCM mice harboring a sarcomere gene
mutation [36]. Further, associations between patterns of ﬁbrosis
and ventricular arrhythmias (Fig. S1) were not reproduced in their
HCM mice, together indicting that distinct somatic events
contribute to variable HCM pathology [36]. Indeed, elevated
BNP levels in HCM patients with VT/VF (Table 1) and the
correlation between the LGE extent and BNP levels (Fig. S2)
indicate the presence of modifying factors because multiple
intrinsic and extrinsic myocardial stress stimulate BNP production
[37,38]. Future studies will be needed to determine somatic factors
that modify arrhythmogenicity in HCM.
Supplementary Fig. S2 related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.jjcc.2014.10.002.
Study limitations
The present study has several limitations. First, the number of
patients was relatively small in this single-center study. However,
the ﬁndings do suggest that the extent of myocardial ﬁbrosis could
be increased in HCM patients with VT/VF harboring sarcomere
gene mutations. Second, some patients with non-sustained VT
could have been overlooked in the intermittent monitoring
process. This disadvantage could potentially be minimized byinterviewing carefully regarding the occurrence of arrhythmias.
Third, there is no standard protocol for the use of therapeutic
medicines, and pharmacologic treatment depended upon each
doctor’s judgment because of the retrospective nature of this
study. However, therapy was administered according to the
guidelines of the American College of Cardiology Foundation/
American Heart Association [7] and the Japanese Circulation
Society [39]. Finally, HCM progresses slowly and a prospective
long-term follow-up study is required to determine whether the
LGE extent predicts the occurrence of VT/VF.
Conclusion
CMR imaging-determined myocardial ﬁbrosis could be in-
creased in HCM patients harboring sarcomere gene mutations with
ventricular arrhythmias. We suggest that careful attention to
antiarrhythmic treatment for these hereditary HCM patients with
extensive myocardial ﬁbrosis may be needed.
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